Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, JAPAN – December 10, 2014 – Astellas Pharma Inc. (Tokyo: 4503), announced today that Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a...
Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the...
Read more about Astellas Named to FTSE4Good Sustainability Index for the Third Year
TOKYO, Japan - December 2, 2014 - Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced that its license agreement with Janssen Biotech, Inc. (“Janssen”) to develop and commercialize...
Tokyo, December 2, 2014 –Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for...
The additional sub-group analyses of C-OPERA in findings regarding the inhibition of joint structural destruction were reported at the American College of Rheumatology/Association of Rheumatology...
Tokyo, Japan - Nov. 4, 2014 – Astellas Pharma Inc. (Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced for the fifth consecutive year, Astellas Group’s global volunteer...
BOSTON and TOKYO, JAPAN – Nov. 4th, 2014 – Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. (Tokyo: 4503) today announced a three-year collaboration to research and develop...
Cambridge, Mass. and Tokyo, Japan, November 4th, 2014 -- Proteostasis Therapeutics, Inc. (“Proteostasis Therapeutics”), a company developing novel therapeutics to address diseases caused by...
Chertsey, England – 24th October 2014 – Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...
Tokyo, Japan– October 22, 2014 – Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced the revision of the package insert for the oral androgen receptor signaling inhibitor XTANDI®...
Tokyo, Japan & South San Francisco CA, October 16, 2014 –Astellas Pharma Inc. (TSE: 4503) and CoMentis, Inc. today announced the companies will end their worldwide exclusive collaboration...
Tokyo, October 14th, 2014 --- Astellas Pharma Inc. (Tokyo: 4503, President & CEO: Yoshihiko Hatanaka, “Astellas”) announced today a research collaboration with an investigator at Harvard...
Tokyo, September 16, 2014 - Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the fourth consecutive year for the...
SAN FRANCISCO, CA and TOKYO, JAPAN – September 10, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced today that the U.S. Food and Drug Administration...
Pfizer Japan Inc. (Tokyo, “Pfizer”) and Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the companies have agreed to terminate the distribution and co-promotion...
Tokyo, August 29, 2014 - Astellas Pharma Inc. (“Astellas”; TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka), today announced that it has pledged donations of 3 million yen...
Read more about Astellas Pharma Supports to Flood Relief Efforts in Western Japan
Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find...
Follow us
